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Gut Microbial Metabolism and 
Nonalcoholic Fatty Liver Disease
Suzanne R. Sharpton, Germaine J.M. Yong, Norah A. Terrault, and Susan V. Lynch
The gut microbiome, the multispecies community of microbes that exists in the gastrointestinal tract, encodes sev-
eral orders of magnitude more functional genes than the human genome. It also plays a pivotal role in human 
health, in part due to metabolism of environmental, dietary, and host-derived substrates, which produce bioactive 
metabolites. Perturbations to the composition and associated metabolic output of the gut microbiome have been 
associated with a number of chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD). Here, we 
review the rapidly evolving suite of next-generation techniques used for studying gut microbiome composition, func-
tional gene content, and bioactive products and discuss relationships with the pathogenesis of NAFLD. (Hepatology 
Communications 2019;3:29-43).
The human gastrointestinal tract harbors tril-lions of bacterial, fungal, and archaeal cells in addition to viral particles. Collectively termed 
the “gut microbiome,” members of these microbial 
communities engage each other and the human host 
by exchanging signaling molecules and substrates, 
interactions that are now emerging as critically 
important in  defining host health.(1) (Table 1) The 
healthy gut microbiome comprises a large diversity 
of phylogenetically distinct microbial species, with 
even greater interindividual diversity observed at the 
subspecies or strain level.(2) Although culture-inde-
pendent studies of the gut microbiome have more tra-
ditionally focused on bacteria, investigation of fungal 
and viral species has increased, leading to their rec-
ognition as integral members of the gut microbiome 
and implicating trans-kingdom interactions in micro-
biome composition and function.(3,4)
The healthy adult gut microbiome encodes sev-
eral orders of magnitude more functional genes than 
the human genome, considerably expanding the 
functional capacity of the human superorganism.(5) 
Whereas average genomic differences between indi-
vidual humans are small, the unique collection of 
microbial species and strains within an individu-
al’s gut microbiome confers a high degree of inter-
personal functional capacity.(6) As the field of gut 
microbiome research has developed, it has become 
clear that the gut microbiome plays a pivotal role in 
defining host health status. This is achieved through 
more traditional host–microbial interactions involv-
ing expression of virulence factors and production of 
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cell-associated ligands (e.g., lipopolysaccharides) that 
influence microbial sensing and response systems 
(e.g., toll-like receptors), which function as immune 
gatekeepers.(7) However, it is increasingly recog-
nized that the products of microbial primary and 
secondary metabolism also modulate host cellular 
physiology and immune responses, thus offering an 
additional avenue by which the gut microbiome and 
its products may influence host health. Among the 
known gut microbiome products that influence host 
cell responses are short-chain fatty acids (SCFAs) 
that serve as energy sources for host cells, interspe-
cies communication or quorum-sensing molecules, 
complex macrolide and non-ribosomal peptides with 
antimicrobial and immunomodulatory capacity, as 
well as vitamins and neuro-signaling molecules.(1,8)
That the gut microbiome is central to human health 
is underscored by an ever-increasing body of literature 
indicating that perturbations to the composition, func-
tion, or metabolic output of the gut microbiome are 
associated with a wide array of chronic disease states.(1) 
Given that the liver receives the majority of its blood 
supply from the intestine through the portal circula-
tion, it is particularly exposed to gut microbiome-de-
rived products. Unsurprisingly, the gut microbiome 
has been implicated in the development of chronic 
liver diseases, including nonalcoholic fatty liver disease 
(NAFLD).(9) Here, we review the following:
• Current methods for studying gut microbiome com-
position, function, and metabolic productivity.
• Factors that shape the gut microbiome.
• Gut microbial metabolism and its effect on human 
health.
• The influence of gut microbial metabolism in the 
pathogenesis of NAFLD.
• Potential therapeutic implications of the gut micro-
biome in the management of NAFLD.
Current Methods in 
Microbiome Research
A variety of methods exist for characterizing 
the gut microbiome. Each of these tools, includ-
ing advantages and current limitations, is reviewed 
in Table 2. Sequencing methods include biomarker 
gene-based sequencing that permit an assessment 
of microbial community composition as well as 
untargeted “shotgun” approaches that enable deter-
mination of the genes encoded (metagenomics) or 
expressed (metatranscriptomics) by the microbi-
ome. We also review mass spectrometry (MS)-based 
platforms that permit identification of proteins 
(metaproteomics) or metabolites (metabolomics) 
produced by the microbiome. Each of these methods 
has been comprehensively reviewed elsewhere,(10-13) 
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taBle 1. DeFinitions oF Key terms
Term Definition
Microbiota Microbes (e.g., bacteria, fungi, viruses) that 
collectively inhabit an ecosystem.




Process of cataloguing microbes through 




Process of cataloguing all the genetic material 
present in a biologic sample.
Metatranscriptomics Process of profiling all expressed genes (RNA) in 
a biologic sample.
Metaproteomics Study of all proteins found in a biologic sample.
Metabolomics Study of all small-molecule chemicals found in a 
biologic sample.
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and therefore this review provides an overview of 
each approach (Fig. 1).
BiomarKer-BaseD miCroBiota 
proFiling
Many studies have catalogued the identity of dis-
tinct microbes present in a specimen through deter-
mination of sequence variants in a specific polymerase 
chain reaction–amplified microbial biomarker gene. 
Commonly used biomarker genes include the 16S 
ribosomal RNA (16S rRNA) gene and the internal 
transcribed spacer 2 region of bacteria and fungi, 
respectively. Due to the lack of a conserved biomarker 
gene across known viral species, no comparable 
approach exists for viruses; their detection currently 
relies on species-specific genes or the reassembly of 
viral genomes from shotgun metagenomic sequencing 





• Useful for samples from sites of low microbial biomass 
(e.g., mucosal biopsies).
• Large reference databases exist and enable  
predictions of functional traits of a community.
• Least expensive sequencing method.
• Lack of species-level resolution in taxonomic identification.
• Functional predictions can be limited.
• Not applicable to viral communities.
• May introduce bias secondary to amplification of a single 
gene.
• Sensitive to technical failures (e.g., primer choice).
Whole (“shotgun”) 
metagenome sequencing
• Measures microbial functional genes.
• Permits parallel microbial taxonomic identification at 
species and/or strain level.
• Deep sequencing depths are often required.
• More expensive and laborious than biomarker-based 
sequencing.
Metatranscriptomics • Evaluates microbial activity and captures dynamic 
variation in transcriptional activity.
• Requires careful sample collection and storage.
• rRNA and host mRNA must be removed.
• May be biased by both mRNA stability and transcription 
rates of microbes.
• Most expensive and laborious sequencing method.
Mass spectrometry-based methods
Metaproteomics • May provide a more accurate view of microbial 
productivity when compared to metatranscriptomics.
• Removal of host-derived proteins is not feasible.
• Protein identification is dependent on reference databases.
Metabolomics • Permits identification of the end products of microbial 
activity.
• Most likely method to identify disease biomarkers and 
facilitate discovery of underlying mechanisms of 
disease.
• Can be performed as targeted or untargeted analyses.
• Identification of metabolites are database- and 
platform-dependent.
• Does not discriminate between identification of  
microbial-derived metabolites and those derived from  
the human host or diet.
Fig. 1. Methods for studying gut microbiome composition, function, and metabolic productivity.
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efforts. Biomarker-based sequencing offers the oppor-
tunity to economically characterize microbial com-
munity membership, structure, and taxonomic relative 
abundance and is particularly useful for large sample 
sizes and when the microbe:host ratio is low (e.g., 
mucosal biopsies). Inferential algorithms based on 
reference bacterial genomes enable predictions of 
evolutionarily conserved functional traits from 16S 
rRNA sequences.(14) Although a useful tool, poor spe-
cies-level resolution in 16S rRNA gene sequencing, 
limited availability of closed bacterial genomes, and 
horizontal gene transfer across microorganisms may 
limit such in silico metagenomic predictions.(15)
WHole metagenome 
seQuenCing
In contrast with biomarker-based sequencing, 
shotgun metagenomic sequencing does not focus on 
a single biomarker gene but rather DNA sequences 
arising from genomes within a microbial community. 
Sequenced fragments are either mapped to a reference 
genomic database or undergo de novo assembly to pro-
duce contiguous regions of microbial genomes, which 
subsequently undergo functional gene annotation 
using specialized platforms.(16) Thus, metagenomic 
sequencing permits parallel identification of microbial 
species and their encoded functional genes within a 
microbiome. More recent human metagenomic studies 
have demonstrated the capacity to follow gut microbi-
omes at strain-level resolution, permitting assessment 
of microbial population dynamics in the neonatal 
gut(17) and tracking of microbial species (and their 
functional genes) that engraft following fecal micro-
bial transplantation (FMT).(18) Although the cost of 
sequencing has declined dramatically over the past 
decade, the need for very large numbers of sequence 
reads per sample to permit sufficient community cov-
erage and metagenomic reconstruction coupled with 
the computational needs to facilitate analysis of such 
large data sets have resulted in shotgun metagenomics 
being more commonly applied to smaller representa-
tive sample sets.
metatransCriptomiCs
Although DNA-based metagenomic sequencing 
permits identification of microbes and encoded genes 
within a microbiome, it does not provide information 
on microbial gene expression. Indeed, even though 
microbiome perturbation is commonly associated 
with established disease, progression and severity 
may be mechanistically linked to changes in the tran-
scriptional program of an otherwise compositionally 
stable pathogenic microbiome. Metatranscriptomic 
shotgun sequencing (also commonly referred to as 
RNA sequencing [RNA-seq]) determines the gene 
expression profile of a microbiome, which, like other 
microbiota or microbiome profiling approaches, 
offers greatest utility when examined longitudinally 
and when related to specific host conditions (e.g., 
disease remission or flare) or, for example, in response 
to dietary inputs.(19) Due to the need for high- quality 
and high-quantity RNA for metatranscriptom-
ics, samples must be appropriately preserved at the 
time of sample collection, i.e., treated with a nucleic 
acid preservative. Following RNA isolation, rRNA, 
which can represent upwards of 75% of total RNA, is 
selectively depleted to enrich for messenger RNA 
(mRNA), long noncoding RNA, and microRNA. The 
mRNA pool is then fragmented and reverse tran-
scribed to produce complementary DNA for sequenc-
ing. Bioinformatic tools similar to those used for 
shotgun metagenomics are then used to map, anno-
tate, and quantify gene expression profiles derived 
from these data sets.(16,20)
Metatranscriptomic analysis permits identification 
of the specific organisms responsible for expression, 
even if the specific gene or pathway of interest is more 
broadly encoded within the metagenome. In addition, 
it also permits directionality to be determined, i.e., 
whether host or microbial genes are expressed. The 
fundamental difference between turnover rates of 
RNA and DNA (minutes or less versus hours or more) 
underpins how metatranscriptome profiles may better 
capture contemporaneous microbiome responses to 
host exposures. This is particularly true for the gut 
microbiome, which is frequently exposed to nutri-
tional and xenobiotic substrates, many of which have 
been shown to exert substantial effects on gut micro-
biome composition and functional gene capacity.(21,22) 
However, it should be noted that mRNA stability, 
which is inherently low in prokaryotes,(23) may differ 
across distinct microbial species, leading to differential 
mRNA degradation across microbes that could skew 
metatranscriptome profiles.(24)
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metaproteomiCs
Facilitated by high-throughput MS, metaproteom-
ics profiles the complement of proteins produced by a 
microbiome, offering a complementary view of micro-
biome function. Given that proteins are inherently 
more stable than mRNA and represent the end prod-
ucts of posttranscriptional and posttranslational regu-
latory mechanisms, this approach may also provide a 
more accurate view of microbial productivity.
Metaproteomics currently uses both gel-based and 
gel-independent liquid chromatography (LC) separa-
tions prior to tandem MS (MS/MS)-based peptide 
identification. Whole proteomes obtained following 
cellular lysis can be fractionated by centrifugation 
based on cellular localization or chemical properties 
(e.g., phosphorylation) prior to peptide and protein 
separation and identification. To identify peptides 
and proteins, high-throughput proteomics software 
pipelines(25) use search algorithms(26) to compare MS/
MS spectra to protein databases or to predicted intact 
masses and fragmentation patterns generated in silico 
from the corresponding metagenome.
Nonuniform peptide ionization and/or selective 
peptide loss during MS detection makes direct quan-
tification of shotgun proteomic data challenging.(27) 
To address this technical challenge, much effort has 
been directed toward stable isotope labeling,(28) which 
enables quantification of the abundance of labeled 
protein under different states, and label-free MS 
methods,(29) which exploit intrinsic MS measurement 
metrics to quantify proteins. Apart from permitting 
quantitative proteomics, stable isotope labeling and 
label-free MS methods have grown in popularity due 
to their simplicity, relatively low cost, and universal 
applicability.
metaBolomiCs
Metabolomics comprises complementary targeted 
and untargeted analytical chemistry techniques, 
including nuclear magnetic resonance spectrometry, 
gas chromatography-MS (GC-MS), and LC-MS, 
that yield vast amounts of information regarding 
the composition of both inorganic and organic com-
pounds associated with a microbiome. These include 
but are not limited to amino acids, lipids, sugars, 
organic acids, secondary bile acids, and more complex 
structures, such as macrolides and polyketides. Similar 
to metaproteomics, spectra are compared with existing 
databases to facilitate metabolite identification and, in 
some cases, source tracking.(30,31)
Traditionally, throughput and range of protein and 
metabolite analyses lag far behind that of nucleic acid 
sequencing platforms (current platforms are predom-
inantly based on MS analyses coupled to slow front-
end separations, such as GC and LC) and are hobbled 
by relatively underdeveloped databases. Fortunately, 
recent advances in rapid gas-phase ion mobility 
spectrometry separations, which distinguish molecu-
lar conformations, have helped to decrease the long 
front-end separation times and increase throughput of 
metabolite detection.(32) In parallel, efforts in the field 
are focused on expanding current databases.
integrating “omiCs” Data
No single “omics” approach can fully decipher 
a mechanistic pathway in disease pathogenesis, 
and combining results from different platforms 
strengthens insight into microbiome–host interac-
tions.(33) The fundamental challenge in “multi-omic” 
approaches is that these processes generate immense 
amounts of multidimensional data. As such, novel 
statistical methods for integrated data analysis that 
combine disparate data sets and standardized quality 
control metrics are constantly evolving. In addition 
to challenges with analytical approaches, data storage 
associated with such data sets requires robust com-
putational resources and infrastructure. However, as 
the field advances and data sets increase in complexity 
and complementarity, the application of systems biol-
ogy approaches promises to expand our mechanistic 
understanding of the gut microbiome across temporal 
and health gradients.
Factors That Shape the Gut 
Microbiome
Microbiome studies, especially those performed 
in human subjects, must account for potential con-
founding factors; therefore, an understanding of 
the factors that shape the gut microbiome is critical 
to experimental design.(34) (Fig. 2) The healthy gut 
microbiome rapidly diversifies over the first several 
years of life,(35,36) typically remains compositionally 
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stable in adulthood,(37,38) and exhibits diversity loss 
in the elderly.(39) The stability of functional gene 
content encoded by the gut microbiome is less well 
studied. Mehta et al.(19) recently performed metag-
enomic and metatranscriptomic sequencing of stool 
samples collected 6 months apart from 308 adults to 
examine temporal stability of gut microbial function. 
Although strain composition and the core microbial 
metagenome were relatively stable over time, unsur-
prisingly, transcriptomic variance exceeded metage-
nomic variance. These findings suggest that a single 
DNA-based measurement of the adult gut microbi-
ome can likely yield reliable information regarding 
composition and gene content but that the metatran-
scriptome (and thus the associated metabolic prod-
ucts) is more dynamic and related to contemporary 
exposures.
Although the host genome has been shown 
to influence the composition of the gut microbi-
ome,(40,41) environmental influences play a more 
significant role in shaping the human gut microbi-
ome.(42) In studies of the gut microbiota of monozy-
gotic twins, fewer than half of detected bacterial taxa 
are shared, indicating that a minority of microbial 
taxa are inherited.(35) Apart from host genetics, a 
number of endogenous and exogenous factors shape 
microbial communities in the gut. These include 
dietary and alcohol intake,(43,44) smoking,(45,46) sex 
and hormonal cycles,(47) diurnal variation,(48) phys-
ical activity,(49) and xenobiotic exposure (including 
antibiotics).(22,50)
A combined analysis of large patient cohorts from 
three continents (Europe, Asia, and North America) 
revealed country-specific microbial signatures, sug-
gesting that culture and geographic location signifi-
cantly impact the gut microbiome composition and 
functional genes it encodes.(51) These geographic 
microbial signatures are also known to be related to 
differences in diet, with functional gene enrichments 
in both babies and adults across geographically dis-
tinct sites closely linked with the proportion of plant 
polysaccharides and simple sugars consumed in the 
diet.(35,52-54) Indeed, short-term dietary interventions 
in healthy adults modulate the gut microbiota, in 
part due to providing a competitive advantage to gut 
microbes capable of extracting energy from the spe-
cific dietary components consumed.(1) Although there 
is currently no standardized approach to account for 
dietary data in human microbiome studies, this is an 
area of ongoing investigation.(55) Nevertheless, there is 
sufficient compelling evidence to suggest that dietary 
intake along with other environmental factors that 
may shape the gut microbiome must be accounted for 
in human microbiome studies.
The Gut Microbiome in 
NAFLD
NAFLD, the liver manifestation of obesity and 
the metabolic syndrome, encompasses a spectrum of 
Fig. 2. Factors that shape the gut microbial community and postulated mechanistic pathways linking gut microbial metabolism to 
the development of NAFLD.
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histopathologic abnormalities ranging from simple 
steatosis to nonalcoholic steatohepatitis (NASH). 
NASH, a more severe phenotype of disease, is associ-
ated with increased risk for development of cirrhosis, 
hepatocellular carcinoma, and liver-related mortal-
ity.(56) Among the 100 million adults with NAFLD 
in the United States, 15% to 20% have NASH.(13) 
Despite the overwhelming burden of NAFLD, there 
are no approved pharmacologic therapies for NAFLD 
in the United States.(57) Although the mechanisms 
that lead to the development of NAFLD and progres-
sion to NASH are not fully elucidated, an ever-grow-
ing body of literature suggests that the gut microbiome 
is implicated in the pathogenesis of NAFLD.
Studies in animal models have provided the most 
compelling evidence for a causal role of the gut 
microbiome in the pathogenesis of NAFLD. Germ-
free mice lacking a gut microbiome are resistant to 
the development of hepatic steatosis,(58) and FMT 
can transmit hepatic steatosis in murine models.(59) 
Moreover, administration of probiotics or antibiotics 
to mice, which can dramatically alter gut microbiome 
composition and has also been shown to influence 
metabolic output in humans,(60) inhibits development 
of high-fat diet-induced hepatic steatosis.(61,62)
A number of cross-sectional human studies have 
demonstrated an association between gut microbiota 
perturbation and the full clinical spectrum of NAFLD, 
including nonalcoholic fatty liver without steatohepa-
titis (NAFL),(63-71) NASH,(64,65,68,69,72-76) NAFLD-
related advanced fibrosis (fibrosis stage >2),(68,76-79) 
and NAFLD-related cirrhosis and hepatocellular car-
cinoma.(77) Several of these studies were performed in 
pediatric cohorts,(63,64,75) and an overwhelming major-
ity of these studies used biomarker-based sequencing 
to profile the gut microbiota. The majority of these 
studies revealed a decrease in overall bacterial diver-
sity in NAFLD, similar to that reported in obesity.(80) 
However, as for other chronic diseases,(81-83) human 
microbiome studies in NAFLD have not identified a 
unique microbial signature. The most consistent finding 
among studies is that higher disease severity, and in par-
ticular advanced fibrosis, is associated with enrichment 
of members of the Bacteroides and Escherichia genera. 
Moreover, the gut microbiome in adults with NAFLD-
related cirrhosis as compared to adults with cirrhosis 
secondary to other etiologies comprises a higher abun-
dance of Porphyromonadaceae and Bacterioidaceae and 
lower abundance of Veillonellaceae.(84)
Discordant results between studies could be attrib-
utable to a variety of factors, such as differences in 
patient age (adults versus children/adolescents) and 
comorbidities (e.g., body mass index, diabetes), geo-
graphic location, definition of NAFLD clinical phe-
notypes, and microbial functional redundancy as well 
as technical differences in stool sample handling, 
sequencing, or statistical analysis methods between 
studies. This is particularly pertinent because many 
of the published studies did not measure or adjust 
for factors known to affect the gut microbiome. The 
inability to find a distinct disease-associated micro-
biota signature is not unique to NAFLD(82) and may 
also be attributable to a failure to detect overrepre-
sented and underrepresented microbial taxa when 
statistical analyses are limited to diversity indices 
and/or comparisons at the phylum or family level 
(the predominant analytical approaches employed 
in NAFLD studies). Secondly, microbial biomarker 
sequencing studies fail to provide information on the 
functional gene content or products of the microbi-
ome, thus potentially missing the crucial microbial 
signature associated with disease. This was demon-
strated in a study of lean and obese individuals who 
were better differentiated by their gut metagenome 
as opposed to their microbiota profile.(85) Finally, 
recent biomarker sequencing studies of large patient 
cohorts have demonstrated that several distinct 
microbiota conformations are evident in patients 
with a given clinical indication and are related to 
differences in immunologic profiles and clinical 
features of disease.(81,86) This implies that within a 
given diseased patient population several pathogenic 
microbiomes may exist; however, such possibilities 
remain unexplored in the field of NAFLD microbi-
ome research.
Among the NAFLD human microbiome stud-
ies performed to date, a few have used one or more 
omic techniques and thus have added new perspec-
tives on functional attributes of the gut microbi-
ome in NAFLD pathogenesis.(63,64,69,70,75,78,79) Da 
Silva et al.(69) performed targeted profiling of eight 
fecal metabolites of interest and found that a higher 
concentration of two fecal SCFAs, propionate and 
isobutyric acid, differentiated adults with NAFL 
from healthy controls. Del Chierico et al.(64) per-
formed an integrated analysis of the gut microbiota 
(by 16S rRNA-seq) and gut metabolome (by tar-
geted metabolomics) in a pediatric cohort with the 
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following clinical phenotypes: NAFL, NASH, and 
obese and healthy controls. In multivariate analysis, 
children with NASH had lower levels of the genus 
Oscillospira, increased levels of the genera Dorea and 
Ruminococcus, and higher levels of two gut metabo-
lites, 2-butanone and 4-methyl-2-pentanone, when 
compared to controls.
Loomba et al.(79) were the first to examine the 
whole gut metagenome, which was integrated with 
serum metabolomics, in adults with NAFLD. The 
prospective cohort study included 86 patients with 
biopsy-proven NAFLD, of which 72 had no or min-
imal fibrosis (stages 0-2) and 14 had advanced fibro-
sis (stages 3-4). Whereas differential abundances in 
microbial gene pathways and serum metabolites did 
not achieve statistical significance after correction 
for multiple testing, 37 bacterial species, including 
Escherichia coli and Bacteroides vulgatas, were differ-
entially represented between minimal and advanced 
fibrosis phenotypes. When these bacterial species 
were incorporated into a model with patient age, 
body mass index, and a microbial diversity index, the 
model possessed an area under the receiver operating 
characteristic curve of 0.936 for detecting advanced 
fibrosis. This finding is concordant with a prior 
observation that B. vulgatus is a contributor to insulin 
resistance.(87) A more recent study by Caussy et al.(78) 
identified a shared gene effect of serum 3-(4-hydroxy-
phenyl)lactate, a microbial-derived metabolite, with 
NAFLD-related advanced fibrosis. Although the 
functional significance of this metabolite is unknown, 
3-(4-hydroxyphenyl)lactate was strongly correlated 
with the abundance of seven bacterial species that were 
previously associated with advanced fibrosis, including 
B. caccae, E. coli, and Clostridium sporogenes.(79)
Gut Microbial Metabolism 
and Interactions With the 
Human Host
Gut microbial metabolites have now been linked 
with specific disease states: autism spectrum disorder 
(4-ethylphenylsulfate)(88) and obesity-associated hepa-
tocellular carcinoma (deoxycholic acid)(89) in murine 
models as well as childhood atopic asthma (12,13-dihy-
droxy-9Z-octadecenoic acid [12,13 Di-HOME])(90) 
and cardiovascular disease (trimethylamine-N-oxide 
[TMAO])(91) in human subjects. A review of the cur-
rent evidence of the causal link between the gut micro-
biota and cardiovascular disease provides an example 
of how mechanistic approaches to studying the gut 
microbiome not only yield insight into disease patho-
genesis but may also provide the foundation by which 
microbiome-targeted therapies can be developed.
Gut microbial metabolism of dietary methyl-
amines contributes to the formation of the following 
three metabolites: choline, betaine, and trimethyl-
amine (TMA).(92) TMA is metabolized by the liver 
to generate TMAO, and manipulation of the gut 
microbiota, either through FMT or administration 
of specific bacterial strains, alters TMAO levels in 
murine models.(93,94) In recent years, many human 
studies have examined the association between serum 
levels of the microbial-derived metabolite TMAO 
and cardiovascular disease. Elevated serum TMAO 
is associated with the degree of atherosclerotic bur-
den and risk of incident cardiovascular events among 
adults presenting with chest pain and those undergo-
ing coronary angiography.(95,96) More recent evidence 
suggests that elevated serum TMAO levels are also 
linked to adipose tissue dysfunction(97) and chronic 
kidney disease.(98) Subsequent mechanistic studies 
identified the biologic function of TMAO to include 
endothelial dysfunction and enhancement of plate-
let hyperreactivity.(99,100) Oral application of a struc-
tural analogue of choline, 3,3-dimethyl-1-butanol, 
inhibited microbial TMA production, lowered serum 
TMAO levels, and prevented development of ath-
erosclerotic lesions, despite a proatherosclerosis diet, 
in an animal model.(101) Together, these data support 
that a microbial-derived metabolite is an important 
contributor to a variety of interrelated cardiomet-
abolic diseases and that targeting the gut microbial 
capacity to produce this metabolite offers a potential 
novel strategy for disease prevention or treatment.
Gut Microbial Metabolism 
in the Pathogenesis of 
NAFLD
Unlike in cardiovascular disease, precise micro-
biome–host mechanisms in NAFLD are not well 
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delineated. However, based on animal studies, many 
of which were performed in models of obesity and 
insulin resistance, several potential mechanistic links 
between the gut microbiome and NAFLD have 
emerged. Postulated mechanisms include dysreg-
ulation of methylamine metabolism, carbohydrate 
fermentation and generation of SCFAs, bile acid 
metabolism, endogenous ethanol production, and 
amino acid metabolism. The gut microbiota may 
also contribute to NAFLD through intestinal barrier 
dysfunction and lipopolysaccharide-induced activa-
tion of toll-like receptor pathways of innate immune 
signaling,(102) but for the purpose of this review, dis-
cussion is limited to disease mechanisms potentially 
mediated by microbial metabolism (Fig. 2).
metHylamine metaBolism
In addition to the role in cardiovascular disease, 
gut microbial metabolism of dietary methylamines, 
specifically choline, may also contribute to the devel-
opment of NAFLD. Choline deficiency contributes 
to the development of fatty liver disease through 
multiple mechanisms, including abnormal phospho-
lipid synthesis, defective very low-density lipopro-
tein secretion, and alterations in the enterohepatic 
circulation of bile acids.(103) Susceptibility to choline 
deficiency was previously attributed to factors such as 
low dietary choline intake, estrogen status, and sin-
gle-nucleotide polymorphisms in specific host genes 
for choline metabolism.(103) However, the discovery of 
gut microbial metabolism of choline to produce TMA 
provides an additional mechanism for low choline 
bioavailability.
A high-fat diet leads to increased gut micro-
bial metabolism of choline and the development of 
hepatic steatosis in mice.(104) Manipulation of dietary 
choline intake in 15 female human subjects resulted 
in variations in the abundance of choline-metaboliz-
ing gut microbial species; abundance of these specific 
microbes along with a single-nucleotide polymor-
phism of a host choline metabolism gene accurately 
predicted the degree to which subjects developed fatty 
liver while on a choline-deficient diet.(105) Subsequent 
human studies have revealed varying associations 
between by-products of methylamine metabolism and 
NAFLD severity,(106,107) but additional studies are 
necessary to decipher the exact role of gut microbial 
methylamine metabolism in NAFLD pathogenesis.
Fermentation oF 
inDigestiBle CarBoHyDrates 
anD proDuCtion oF sCFas
Complex carbohydrates undergo microbial fermen-
tation predominantly in the colon, resulting in the 
production of SCFAs, including acetate, propionate, 
and butyrate. SCFAs provide the majority of energy 
needs for intestinal epithelial cells, but they also cross 
the intestinal epithelial barrier and mediate a variety 
of biologic activities, including modulation of immune 
function and exerting antiproliferative effects, in part 
by signaling through G protein-coupled receptors in 
multiple tissue sites.(108,109)
Fecal SCFA concentrations are increased in geneti-
cally obese mice,(80) and germ-free mice with low levels 
of gut SCFAs are protected from diet-induced obe-
sity.(110) These data suggest that significantly elevated 
fecal SCFAs, indicative of increased energy extraction 
from dietary input, are a hallmark of obesity. However, 
in contrast to these findings, an increase in butyr-
ate-producing bacteria has been shown to prevent 
diet-induced hepatic steatosis and bile acid dysreg-
ulation and its associated hepatitis in murine mod-
els.(111,112) Moreover, in humans, increasing colonic 
propionate prevented weight gain in overweight 
adults,(113) and the beneficial metabolic effects of 
FMT from lean to obese donors were primarily 
associated with an increased abundance of butyr-
ate-producing bacterial strains in the gut.(114) These 
contradictory findings are likely attributable to differ-
ing end-organ effects of individual or combinations 
of SCFAs, including varying effects on energy expen-
diture, production of satiety hormones, and central 
appetite regulation.(108)
Bile aCiD transFormations 
By tHe gut miCroBiota
Bile acids are steroid-derived molecules synthesized 
in the liver and secreted into the intestinal lumen 
that facilitate lipid absorption and additionally reg-
ulate metabolism by activation of a number of host 
receptors, including farnesoid X receptor (FXR) and 
the membrane-associated G protein-coupled receptor 
(TGR5).(115) Distinct bile acids have varying affini-
ties for host receptors and may act either as recep-
tor agonists or antagonists, with subsequent effects 
on the regulation of basal metabolism and energy 
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expenditure, lipid metabolism, nitric oxide synthe-
sis, intestinal motility and permeability, and immune 
response.(116,117)
In addition to their effects on the host, bile acids 
prevent intestinal bacterial overgrowth, both directly 
through membrane-damaging effects and indirectly 
through induction of antimicrobial protein  expression; 
thus, they also play an important role in shaping gut 
microbiome membership.(118) Indeed, microbial bile 
acid resistance offers a fitness advantage in the gut 
and is commonly complemented by the capacity to 
deconjugate bile acids and convert primary bile acids 
to secondary bile acids. Germ-free mice or antibiot-
ic-treated mice exhibit low concentrations of con-
jugated bile acids, pointing to a central role of gut 
microbiome in regulating bile acid composition.
Animal models have revealed that lean and obese 
mice have a differential abundance of various bile 
acids.(119) Human studies have noted elevated total 
serum bile acids, with an altered ratio of secondary to 
primary bile acids, in adults with NAFLD.(73,120,121) 
Of interest, administration of the FXR agonist obeti-
cholic acid led to improvement in NASH and insulin 
sensitivity in randomized controlled trials in adults, 
indicating an important role for bile acid signaling 
in NAFLD and the potential for therapeutic inter-
vention targeting bile acid receptors.(122,123) Thus, 
dysregulation of the reciprocal relationship between 
the human gut microbiome and bile acids has the 
capacity to significantly modulate FXR and TGR5 
signaling, modulating host metabolism and immunity, 
and offers an attractive mechanistic hypothesis link-
ing the gut microbiome and metabolic diseases, such 
as NAFLD.(124) For a comprehensive overview of gut 
microbiome–bile acid crosstalk in the pathogenesis of 




Hepatic genes involved in alcohol metabolism, 
including alcohol dehydrogenase, are up-regu-
lated in NAFLD.(126,127) A number of studies have 
demonstrated that children and adolescents with 
NAFLD have increased serum ethanol levels,(63,64,75) 
although this finding is not consistent across all 
studies.(69) The gut microbiome can generate eth-
anol from dietary precursors, and manipulation 
of the gut microbiome is known to alter endoge-
nous ethanol production.(128) A common finding in 
NAFL and NASH is enrichment in Escherichia and/
or Lactobacillus genera,(65,68-71,74,75,77-79) which have 
the capability to produce ethanol. These findings 
suggest that increased endogenous ethanol produc-
tion by the gut microbiome could contribute to the 
pathogenesis of NAFLD. However, a recent study 
demonstrated that elevated serum ethanol may also 
be attributed to insulin-dependent impairments of 
alcohol dehydrogenase activity in the liver, indepen-
dent of endogenous alcohol production by the gut 
microbiome,(129) pointing to the existence of distinct 
disease mechanisms that may converge on a com-
mon clinical manifestation and are plausibly linked 
to gut microbiome functional differentials within 
this patient population.
amino aCiD BiosyntHesis anD 
metaBolism
The gut microbiome influences amino acid 
homeostasis, in part due to biosynthesis and 
metabolism of aromatic amino acids (AAAs) and 
branched-chain amino acids (BCAAs). Elevated 
serum BCAA, postulated to be secondary to pertur-
bations in gut microbial metabolism, has been iden-
tified as a potential biomarker for insulin resistance 
in several cohort studies.(130,131) Specifically, two 
bacterial species, Prevotella copri and B. vulgatus, are 
associated with enriched biosynthetic potential for 
BCAAs and a reduced potential for BCAA trans-
port into bacterial cells in adults with insulin resis-
tance.(87) Intriguingly, a more recent study found 
that B. vulgatus was one of the most abundant gut 
microbes in adults with NAFLD-related advanced 
fibrosis.(79)
Perturbations in microbial metabolism of AAAs 
and BCAAs and ensuing alterations in the serum 
metabolite profile have more recently been identi-
fied in NAFLD.(70,132) Hoyles et al.(70) performed 
an integrated analysis of the gut metagenome, 
hepatic transcriptome, and serum and urine metab-
olomes in a cohort of women with obesity but with-
out diabetes. Compared to those without NAFL, 
women with NAFL had significant alterations 
in the gut metagenome, including differences in 
BCAA and AAA pathways, as well as in the serum 
metabolome. Specifically, serum phenylacetic acid, 
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an AAA-derived microbial metabolite, was strongly 
correlated with hepatic steatosis in this cohort. 
This metabolite was subsequently found to induce 
hepatic steatosis both in vitro (primary culture of 
human hepatocytes) and in vivo (murine model), 
suggesting a potential causal role in NAFL patho-
genesis.(70) This study provides a proof-of-concept 
prototype of how integrated multi-omic analyses in 
human subjects combined with in vitro and in vivo 
mechanistic studies can facilitate identification of 
possible microbial-driven mechanistic pathways in 
NAFLD.
Gut Microbiome-Targeted 
Therapy in the Management 
of NAFLD
The prospect of targeting the gut microbiome in 
the management of NAFLD offers a novel strategy 
for disease prevention or management. A diverse 
array of strategies to manipulate the gut microbiome 
exist and include dietary interventions, probiotics 
(culture of living microorganisms), prebiotics (fer-
mentable dietary fibers that stimulate the growth 
and survival of probiotics), synbiotics (combina-
tion of probiotics and prebiotics), antibiotics, and 
FMT.(1) Moreover, bariatric surgery results in rapid 
and sustained shifts in the gut microbiome.(133) 
Damms-Machado et al.(134) found that the gut 
microbiome in adults with obesity who underwent 
bariatric surgery shifted within 6 months after sur-
gery toward a microbial profile found in adults with 
normal body weight. Recent studies have revealed 
the existence of distinct and niche-specific microbial 
communities along the length of the gastrointestinal 
tract and that the composition of these communi-
ties influence successful engraftment of exogenous 
microbes,(135,136) suggesting that future microbial 
interventions may be personalized based on an 
individual’s gut microbiome. However, large-scale 
interventional trials with therapies targeting the 
gut microbiome in NAFLD are lacking, and a bet-
ter understanding of the complexities of microbial 
metabolism and microbe–host interactions is nec-
essary to inform the development of gut microbi-
ome-targeted therapies for this patient population.
Conclusions
An ever-growing body of preclinical and clinical 
literature supports that changes to the composition, 
function, and/or metabolic output of the gut microbi-
ome are associated with NAFLD; however, the exact 
mechanistic links remain elusive. Integrated multi-
omic analyses, based on high-throughput sequencing 
and MS platforms, are now yielding more comprehen-
sive views of gut microbiome functional capacity and 
biochemical output in NAFLD. Additional longitu-
dinal prospective cohort studies, which are designed 
to account for various environmental factors that can 
shape the gut microbiome and are complemented by in 
vitro and in vivo mechanistic studies, are necessary to 
delineate microbiome–host interactions that contrib-
ute to NAFLD pathogenesis. Improved knowledge of 
the contribution of gut microbial metabolism to liver 
health could yield the foundation for the development 
of novel microbiota-targeted precision interventions 
for the treatment or management of NAFLD.
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